Christopher A. Simon
Principal executive officer pay for Christopher A. Simon, by year and company, from pay-versus-performance disclosure. Every figure links to its source on the company page.
HAEMONETICS CORP (HAE) FY2021–FY2026
Beat peersTSR -57% vs peer group -63% over FY2021–FY2026
Paid for declineCAP $6,611,926→$8,116,821 while $100 invested went $110.99→$48.23 (FY2021–FY2026)
| Fiscal year | SCT total | Comp actually paid |
|---|---|---|
| FY2021 | $8.6M | $6.6M |
| FY2022 | $8.7M | -$2.4M |
| FY2023 | $10.7M | $18.1M |
| FY2024 | $11.5M | $10.2M |
| FY2025 | $10.7M | $1.3M |
| FY2026 | $12.0M | $8.1M |
The company's "$100 invested" index ran $110.99 at FY2021 → $48.23 by FY2026 — an annualized return of -15.4%.
Track record
1 measurable tenure in the pay-versus-performance disclosure window. Best annualized TSR: -15.4%/yr at HAE ( FY2021–FY2026). See the CEO track-record ranking for context.